The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons

European Journal of Pharmacology

Volumn 406, Issue 1, 2000, Pages 25-32

  Adelsberger, Helmuth ^a   Quasthoff, Stefan ^b   Grosskreutz, Julian ^b   Lepier, Alexandra ^c   Eckel, Florian ^c   Lersch, Christian ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Colorectal cancer; Dorsal root ganglia; Hippocampal neuron; Neuropathy; Sural nerve

Indexed keywords

CARBAMAZEPINE; OXALIPLATIN;

ANIMAL EXPERIMENT; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; HIPPOCAMPUS; HUMAN CELL; NERVE CELL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; RAT; REFRACTORY PERIOD; SENSORIMOTOR NEUROPATHY; SODIUM CURRENT; SPINAL GANGLION; SURAL NERVE; VAGUS NERVE;

4-AMINOPYRIDINE; ACTION POTENTIALS; ANIMALS; CARBAMAZEPINE; ELECTRIC STIMULATION; GANGLIA, SPINAL; HIPPOCAMPUS; KINETICS; MEMBRANE POTENTIALS; NERVE FIBERS; NEURONS, AFFERENT; ORGANOPLATINUM COMPOUNDS; POTASSIUM CHANNELS; RATS; SODIUM CHANNELS; SURAL NERVE; TETRAETHYLAMMONIUM; TETRODOTOXIN; TIME FACTORS; VAGUS NERVE;

EID: 0034613403     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00667-1     Document Type: Article

References (23)

1. Adelsberger H., Quasthoff S., Grosskreutz J., Marstaller B., Lersch C. Alteration of sodium channel inactivation kinetics on rat sural nerve by the chemotherapeutic agent oxaliplatin. Biol. Chem. 380:1999;S132. (Suppl.).
2. Baker M., Bostock H., Grafe P., Martius P. Function and distribution of three types of rectifying channels in rat spinal root myelinated axons. J. Physiol. (London). 383:1987;45-67.
3. Becouarn Y., Rougier P. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin. Oncol. 25(2):1998;23-31. (Suppl. 5).
4. Black J.A., Dib-Hajj S., McNabola K., Jeste S., Rizzo M.A., Kocsis J.D., Waxman S.G. Spinal sensory neurons express multiple sodium channel alpha-subunit mRNAs. Brain Res. Mol. Brain Res. 43:1996;117-131.
5. Bostock H., Sears T.A., Sherratt R.M. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J. Physiol. (London). 313:1983;301-315.
6. Boughattas N. Effects of the anticancer agent oxaliplatin on the excitability properties of the peripheral nervous system. Proc. Am. Assoc. Cancer Res. 35:1994;2583.
7. Cummins T.R., Waxman S.G. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J. Neurosci. 17:1997;3503-3514.
8. Dib-Hajj S.D., Tyrrell L., Black J.A., Waxman S.G. NaN, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. Proc. Natl. Acad. Sci. U. S. A. 95:1998;8963-8968.
9. Extra J.-M., Espie M., Calvo F., Ferme C., Mignot L., Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. 25:1990;299-303.
10. Extra J.-M., Marty M., Brienza S., Misset J-L. Pharmacokinetics and safety profile of oxaliplatin. Semin. Oncol. 25(2):1998;13-22. (Suppl. 5).
11. Felts P.A., Yokoyama S., Dib-Hajj S., Black J.A., Waxman S.G. Sodium channel α-subunit mRNAs I, II, III, NaG, Na6 and hNE (PN1): different expression patterns in developing rat nervous system. Mol. Brain Res. 45:1997;71-82.
12. Fitzgerald E.M., Okuse K., Wood J.N., Dolphin A.C., Moss S.J. cAMP-dependent phosphorylation of the tetrodotoxin-resistant voltage-dependent sodium channel SNS. J. Physiol. (London). 216:1999;433-446.
13. Gerard B., Bleiberg H., Van Daele D., Gil Th., Hendlisz A., DiLeo A., Fernez B., Brienza S. Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer. Anti-Cancer Drugs. 9:1998;301-305.
14. Grafe P., Bostock H., Schneider U. The effects of hyperglycaemic hypoxia on rectification in rat dorsal root axons. J. Physiol. (London). 480:1994;297-307.
15. Hamill O.P., Marty A., Neher E., Sakmann B., Sigworth F.J. Improved patch clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pfluegers Arch. 391:1981;85-100.
16. Hirade M., Yasuda H., Omatsu-Kanbe M., Kikkawa R., Kitasato H. Tetrodotoxin-resistant sodium channels of dorsal root ganglion neurons are readily activated in diabetic rats. Neuroscience. 90:1999;933-939.
17. Lambert E.H., Dyck P.J. Compound action potentials of sural nerve in vitro in peripheral neuropathy. Dyck P.J., Thomas P.K., Griffin J.W., Low P.A., Poduslo J.F. Peripheral Neuropathy. 1993;672-684 WB Saunders, Philadelphia.
18. Levi F., Perpoint B., Garufi C., Focan C., Chollet P., Depres-Brummer P., Zidani R., Brienza S., Itzhaki M., Iacobelli S. Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur. J. Cancer. 29(2):1993;1280-1284.
19. Marsh S.J., Stansfield C.E., Brown D.A., Davey R., McCarthy D. The mechanism of action of capsaicin on sensory C-type neurons and their axons in vitro. Neuroscience. 23:1987;275-289.
20. Raymond E., Faivre S., Woynarowski J.M., Chaney S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. 25(2):1998;4-12. (Suppl. 5).
21. Rizzo M.A. Successful treatment of painful traumatic mononeuropathy with carbamazepine: insights into a possible molecular pain mechanism. J. Neurol. Sci. 152:1997;103-106.
22. Waxman S.G., Kocsis J.D., Black J.A. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J. Neurophysiol. 72(1):1994;466-470.
23. Willow M., Kuenzel E.A., Catterall W.A. Inhibition of voltage-gated sodium channels in neuroblastoma cells and synaptosomes by the anticolvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol. 25(2):1984;228-234.